All AbMole products are for research use only, cannot be used for human consumption.
For this product's availability, delivery time and price, please email inquiry@abmole.com directly or click the "Inquiry Now" button below.
AGI-43192 is a potent inhibitor of methionine adenosyltransferase 2A (MAT2A). AGI-43192 is a potent, but limited brain-penetrant compound. AGI-43192 has the potential for exploring the effects of SAM modulation in the central nervous system (CNS) and research of cancer disease.
| Molecular Weight | 484.86 |
| Formula | C23H16ClF3N6O |
| CAS Number | 2377491-54-6 |
| Form | Solid |
| Solubility (25°C) | DMSO 13.89 mg/mL (ultrasonic and warming and heat to 60°C) |
| Storage |
Powder -20°C 3 years ; 4°C 2 years In solvent -80°C 6 months ; -20°C 1 month |
| Related Somatostatin Receptor Products |
|---|
| Pasireotide
Pasireotide is a somatostatin analog with a 40-fold increased affinity to somatostatin receptor 5 compared to other somatostatin analogs. |
| Octreotide Acetate
Octreotide acetate(SMS 201995 acetate) is a long-acting octapeptide with pharmacologic actions mimicking those of the natural hormone somatostatin. |
| Cyclosomatostatin acetate
Cyclosomatostatin acetate is a potent somatostatin (SST) receptor antagonist. Cyclosomatostatin acetate can inhibit somatostatin receptor type 1 (SSTR1) signaling and decreases cell proliferation, ALDH+ cell population size and sphere-formation in colorectal cancer (CRC) cells. |
| FK962
FK962 is an enhancer of somatostatin release, exerts cognitive-enhancing actions. |
| Lanreotide
Lanreotide is a somatostatin analogue, acts as an inhibitor of growth hormone (GH). |
All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.
